KU Leuven 10 Laboratory of Lipid Metabolism and Cancer, Leuven Institute for Single Cell Omics (LISCO) and Leuven Cancer Institute (LKI), Department of Oncology Leuven, Belgium
Auto-generated profile, based on publicly available information
Jakub Idkowiak
KU Leuven 10 Laboratory of Lipid Metabolism and Cancer, Leuven Institute for Single Cell Omics (LISCO) and Leuven Cancer Institute (LKI), Department of Oncology Leuven, Belgium
A wide range of compounds that occur in the genus Hypericum are listed as effective drugs of natural origin. The main biological activities of several Hypericum representatives are due to the presence of naphthodianthrones, phloroglucinols, and other diverse groups of secondary metabolites that synergistically contribute to their therapeutic effects. The regulation of biosynthesis of hypericin as the key bioactive naphthodianthrone remains uncertain. Here, we present liquid chromatography mass spectrometry-based phenotyping of 17 Hypericum species, the results of which suggest an important role for skyrin and its derivatives in the polyketide pathway that leads to hypericin formation. Moreover, we report for the first time the presence of new metabolites in the genus Hypericum that are related to classes of anthraquinones, their derivatives, and phloroglucinols. As skyrin and other species of anthraquinones are rarely found in higher plants but frequently occur in fungal microorganisms, the obtained results suggest that further research on the synthesis pathways of hypericin and the role of anthraquinone derivatives in plant metabolism should be carried out. The fact that these compounds are commonly synthesized in endophytic fungi and perhaps there is some similarity in the metabolic pathways between these organisms should also be investigated.
Recent advances in spatial omics methods are revolutionising biomedical research by enabling detailed molecular analyses of cells and their interactions in their native state. As most technologies capture only a specific type of molecules, there is an unmet need to enable integration of multiple spatial-omics datasets. This, however, presents several challenges as these analyses typically operate on separate tissue sections at disparate spatial resolutions. Here, we established a spatial multi-omics integration pipeline enabling co-registration and granularity matching, and applied it to integrate spatial transcriptomics, mass spectrometry-based lipidomics, single nucleus RNA-seq and histomorphological information from human prostate cancer patient samples. This approach revealed unique correlations between lipids and gene expression profiles that are linked to distinct cell populations and histopathological disease states and uncovered molecularly different subregions not discernible by morphology alone. By its ability to correlate datasets that span across the biomolecular and spatial scale, the application of this novel spatial multi-omics integration pipeline provides unprecedented insight into the intricate interplay between different classes of molecules in a tissue context. In addition, it has unique hypothesis-generating potential, and holds promise for applications in molecular pathology, biomarker and target discovery and other tissue-based research fields.
Renal cell carcinoma (RCC) represents the most common type of kidney cancer and, despite the progress of surgical and medical management, is associated with high mortality. In this study, we demonstrate that RCC-related processes change body fluids sphingolipid concentrations, which may be used to monitor tumor presence using non-invasive lipid-based blood and urine tests. We investigate 674 plasma, urine, and tissue samples from 369 RCC patients and controls. For the first time, we show the significant concentration changes of low abundant sulfatides in plasma and urine of RCC patients. Elevated concentrations of lactosylsulfatides, decreased concentrations of sphingomyelins with long saturated N-fatty acyls and sulfatides with hydroxylated fatty acyls are the crucial alternations in RCC. These changes are stage-dependent and are more emphasized in late-stage RCC. Similar trends in body fluids and tissues indicate that RCC widely influences lipid metabolism and highlights the potential of lipidomic profiling for cancer detection.
Background Pancreatic cancer is one of the most aggressive malignancies with a 5-year relative survival rate of only 13%. Its poor prognosis is largely attributed to the lack of reliable tools for early detection. Current diagnostic standards rely on imaging methods that are invasive, costly, and often inadequate to detect early-stage disease. A noninvasive blood-based test with high sensitivity and specificity could substantially improve patient outcomes. Methods Lipid concentrations in plasma and serum samples were determined by ultrahigh-performance supercritical fluid chromatography–mass spectrometry, and multivariate statistical modeling was used to analyze lipid profiles and differentiate between groups. Results Here, we present results from a pilot study evaluating lipidomic profiling of prospectively collected plasma and serum samples from patients with pancreatic ductal adenocarcinoma (PDAC, n = 177), healthy controls (n = 218), and high-risk individuals for pancreatic cancer (n = 93). The lipidomic test distinguishes PDAC patients from healthy controls with an accuracy exceeding 95%, including robust detection of early-stage cases and even individuals with low CA 19-9 secretion. The sensitivity is approximately 30% higher than that of CA 19-9. In high-risk individuals, the method achieves a specificity of over 96% (95% CI, 89–99%), comparable to established imaging-based approaches. Conclusions This pilot study demonstrates the promising potential of lipidomic profiling as a noninvasive, blood-based screening tool for pancreatic cancer. The method outperforms current biomarkers, maintains high diagnostic accuracy in early-stage disease, and performs reliably in high-risk populations. These findings support the initiation of a clinical trial aimed at validating the lipidomic test for the early detection of PDAC.
Duplication of PMP22 causes Charcot-Marie-Tooth disease type 1A (CMT1A) and is known to disrupt the lipid metabolism in myelinating Schwann cells by unknown mechanisms. By using two CMT1A mouse models overexpressing human PMP22 , we discovered that PMP22 dose-dependently downregulates genes that are involved in lipid and cholesterol metabolism. Lipidomic analysis on CMT1A mouse sciatic nerves confirmed lipid metabolic abnormalities primarily associated with cholesterol and sphingolipids. We observed similar lipidomic profiles and downregulation of genes associated with lipid metabolism in human CMT1A patient induced pluripotent stem cell-derived Schwann cell precursors (iPSC-SCPs). We confirmed these findings by demonstrating altered lipid raft dynamics and plasma membrane fluidity in CMT1A iPSC-SCPs. Additionally, we identified impaired cholesterol incorporation in the plasma membrane due to altered lipid storage homeostasis in CMT1A iPSC-SCPs, which could be modulated by changing the lipid composition of the cell culture medium. These findings suggest that PMP22 plays a role in regulating the lipid composition of the plasma membrane and lipid storage homeostasis. Targeting lipid metabolism may hold promise as a potential treatment for CMT1A patients. Graphical Highlights: PMP22 copy number causes a dose-dependent suppression of cholesterol and lipid biosynthesis in peripheral nerves of CMT1A mice Lipid composition is altered in the sciatic nerves of CMT1A mice and in the membranes of patient derived iPSC-SCPs, with a significant reduction in sphingolipids CMT1A iPSC-SCPs show decreased plasma membrane lipids required for regulating lipid raft dynamics, membrane fluidity, and membrane order Lipid storage misregulation is key in the pathogenesis of CMT1A
Cancer cells that seed in the lung require lipids often produced by alveolar type II (AT2) cells. However, whether overt metastases depend on AT2 cell–derived lipids and whether AT2 cells can be targeted to reduce metastasis growth remains unknown. We discovered that breast cancer–derived lung metastases stimulate the proliferation of AT2 cells in their vicinity and reprogram them into lipid feeder cells in mice and patients using spatial analysis. Mechanistically, the metastasis secretome activates the transcription factor sterol regulatory element–binding transcription factor 1 (SREBP-1) in AT2 cells, enhancing the expression of key de novo lipid synthesis genes, including fatty acid synthase (FASN) and glycerol-3-phosphate acyltransferase 1 (GPAM). Deleting Fasn selectively in AT2 cells or targeting FASN and GPAM systemically significantly impairs lung metastasis growth in mice. In summary, we discovered that overt metastases reprogram AT2 cells and that targeting the lipid metabolism of AT2 cells impairs metastasis growth. Significance: Current therapies in oncology targeting the cancer or immune cell compartment of tumors show limited efficacy against breast cancer–derived metastases. We discovered that decreasing the lipid metabolism of lung resident AT2 cells is sufficient to impair lung metastasis growth in mice without apparent adverse effects.